fig5

Figure 5. SC263 xenograft models in CB17 Scid mice are unsuitable for investigating cetuximab resistance. (A) Tumor kinetics after s.c. injection with 2.5 × 10⁶ + 25% Matrigel SC263-S cells in CB17 Scid mice (n = 27); (B) Tumor kinetics after s.c. injection with 10 × 10⁶ + 12 mg/mL Geltrex SC263-S cells in CB17 Scid mice (n = 10). Each line represents the data of one individual mouse; (C) Tumor kinetics of SC263-R tumor-bearing CB17 Scid mice following treatment with vehicle (PBS, n = 6), cetuximab low (2.5 mg/kg, n = 7), cetuximab medium (10 mg/kg, n = 7), and cetuximab high (50 mg/kg, n = 7). The green area in the graph represents the treatment period (starting from day 7). Data represent mean ± SD. HNSCC: Head and neck squamous cell carcinoma; -S: cetuximab-sensitive HNSCC cell line; -R: cetuximab-resistant HNSCC cell line; s.c.: subcutaneous.